Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | March 12, 2025 | March 14, 2025 |
| Twist Bioscience CorpTWST · Entity 3619 | Director | July 23, 2019 | October 09, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MADRIGAL PHARMACEUTICALS, INC.
Report date March 12, 2025 · Filed March 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 350,076 |
Ending reported balance
After 2025-03-13 transaction · row 16
16 source rows · reconciled sequenceRow 1 · 2025-03-12 · Exercise / conversion · Acquired 1,728 · Balance 351,804 Row 2 · 2025-03-12 · Exercise / conversion · Acquired 6,000 · Balance 357,804 Row 3 · 2025-03-12 · Sale · Disposed 1,587 · Balance 356,217 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.00 to $330.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Row 4 · 2025-03-12 · Sale · Disposed 2,759 · Balance 353,458 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.00 to $331.89, inclusive. Row 5 · 2025-03-12 · Sale · Disposed 2,382 · Balance 351,076 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $332.01 to $332.88, inclusive. Row 6 · 2025-03-12 · Sale · Disposed 800 · Balance 350,276 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $333.39 to $333.89, inclusive. Row 7 · 2025-03-12 · Sale · Disposed 200 · Balance 350,076 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.95 to $334.99, inclusive. Row 8 · 2025-03-13 · Exercise / conversion · Acquired 7,742 · Balance 357,818 Row 9 · 2025-03-13 · Sale · Disposed 1,951 · Balance 355,867 F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $322.02 to $323.00, inclusive. Row 10 · 2025-03-13 · Sale · Disposed 1,649 · Balance 354,218 F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.02 to $323.97, inclusive. Row 11 · 2025-03-13 · Sale · Disposed 900 · Balance 353,318 F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.16 to $324.84, inclusive. Row 12 · 2025-03-13 · Sale · Disposed 800 · Balance 352,518 F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.34 to $325.955, inclusive. Row 13 · 2025-03-13 · Sale · Disposed 1,000 · Balance 351,518 F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $327.19 to $328.18, inclusive. Row 14 · 2025-03-13 · Sale · Disposed 400 · Balance 351,118 F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.20 to $329.165, inclusive. Row 15 · 2025-03-13 · Sale · Disposed 967 · Balance 350,151 F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $329.22 to $330.20, inclusive. Row 16 · 2025-03-13 · Sale · Disposed 75 · Balance 350,076 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.06 · Expires 2025-06-16 | Direct | 7,742 |
Reported balance
After 2025-03-12 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2025-03-12 · Exercise / conversion · Disposed 1,728 · Balance 7,742 F16: The shares underlying this stock option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $111.06 · Expires 2025-06-17 | Direct | 0 |
Reported balance
After 2025-03-12 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2025-03-12 · Exercise / conversion · Disposed 6,000 · Balance 0 F16: The shares underlying this stock option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.06 · Expires 2025-06-16 | Direct | 0 |
Reported balance
After 2025-03-13 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2025-03-13 · Exercise / conversion · Disposed 7,742 · Balance 0 F16: The shares underlying this stock option are fully vested and exercisable. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 11,210 |
Reported balance
Holding disclosure · report date 2025-03-12 · row 17
Holding and transaction disclosures are not merged.
1 source rowRow 17 · Balance 11,210 F13: Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 1,261 |
Reported balance
Holding disclosure · report date 2025-03-12 · row 18
Holding and transaction disclosures are not merged.
1 source rowRow 18 · Balance 1,261 F14: These securities are held by Bay City Capital LLC ("BCC"). Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 21,000 |
Reported balance
Holding disclosure · report date 2025-03-12 · row 19
Holding and transaction disclosures are not merged.
1 source rowRow 19 · Balance 21,000 F15: Represents shares held indirectly by Dr. Craves through the Craves Family Foundation. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.00 to $330.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.00 to $331.89, inclusive.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $332.01 to $332.88, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $333.39 to $333.89, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.95 to $334.99, inclusive.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $322.02 to $323.00, inclusive.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.02 to $323.97, inclusive.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.16 to $324.84, inclusive.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.34 to $325.955, inclusive.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $327.19 to $328.18, inclusive.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.20 to $329.165, inclusive.
F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $329.22 to $330.20, inclusive.
F13: Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust.
F14: These securities are held by Bay City Capital LLC ("BCC"). Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.
F15: Represents shares held indirectly by Dr. Craves through the Craves Family Foundation.
F16: The shares underlying this stock option are fully vested and exercisable.
Twist Bioscience Corp
Report date July 23, 2019 · Filed October 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.41 · Expires 2029-07-22 | Direct | 5,590 |
Reported balance
After 2019-07-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-23 · Grant · Acquired 5,590 · Balance 5,590 F1: 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dermira, Inc.
Report date February 20, 2020 · Filed February 24, 2020
Section 16 reporting ended · disclosed 2020-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote 2 | 0 |
Reported balance
After 2020-02-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: The securities are held directly by Bay City Capital LLC ("BCC LLC"). Dr. Craves disclaims beneficial ownership over the securities owned by BCC LLC except to the extent of his pecuniary interest, if any, in the securities by virtue of his role as managing director of BCC LLC. This report shall not be deemed an admission that the Dr. Craves is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote 3 | 0 |
Reported balance
After 2020-02-20 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-02-20 · Disposition to issuer · Disposed 3,441,075 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: The securities are held directly by Bay City Capital Fund V, L.P. ("Fund V"). Dr. Craves disclaims beneficial ownership over the securities owned by Fund V, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in Bay City Capital LLC, which is the manager of Fund V's general partner, Bay City Capital Management V LLC. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote 4 | 0 |
Reported balance
After 2020-02-20 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-02-20 · Disposition to issuer · Disposed 65,572 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: The securities are held directly by Bay City Capital Fund V Co-Investment Fund, L.P. ("Co-Investment V"). Dr. Craves disclaims beneficial ownership over the securities owned by Co-Investment V, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in Bay City Capital LLC, which is the manager of Co-Investment V's general partner, Bay City Capital Management V LLC. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote 5 | 0 |
Reported balance
After 2020-02-20 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2020-02-20 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F5: The securities are held directly by the Fred Craves Family Foundation ("Foundation"). Dr. Craves serves as the chief executive officer of the Foundation. Dr. Craves disclaims beneficial ownership over and does not have a pecuniary interest in shares held by the Foundation. This report shall not be deemed an admission that the Dr. Craves is the beneficial owner of such shares. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2025-06-10 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-20 · Disposition to issuer · Disposed 10,334 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F6: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.82 · Expires 2026-06-20 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-20 · Disposition to issuer · Disposed 10,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F6: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.01 · Expires 2027-06-12 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F6: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.95 · Expires 2028-06-12 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F6: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2029-06-03 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F6: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-02-20 · Disposition to issuer · Disposed 3,000 · Balance 0 F7: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: The securities are held directly by Bay City Capital LLC ("BCC LLC"). Dr. Craves disclaims beneficial ownership over the securities owned by BCC LLC except to the extent of his pecuniary interest, if any, in the securities by virtue of his role as managing director of BCC LLC. This report shall not be deemed an admission that the Dr. Craves is the beneficial owner of such shares.
F3: The securities are held directly by Bay City Capital Fund V, L.P. ("Fund V"). Dr. Craves disclaims beneficial ownership over the securities owned by Fund V, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in Bay City Capital LLC, which is the manager of Fund V's general partner, Bay City Capital Management V LLC.
F4: The securities are held directly by Bay City Capital Fund V Co-Investment Fund, L.P. ("Co-Investment V"). Dr. Craves disclaims beneficial ownership over the securities owned by Co-Investment V, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in Bay City Capital LLC, which is the manager of Co-Investment V's general partner, Bay City Capital Management V LLC.
F5: The securities are held directly by the Fred Craves Family Foundation ("Foundation"). Dr. Craves serves as the chief executive officer of the Foundation. Dr. Craves disclaims beneficial ownership over and does not have a pecuniary interest in shares held by the Foundation. This report shall not be deemed an admission that the Dr. Craves is the beneficial owner of such shares.
F6: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
F7: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,742 | $0.00 Strike: $65.06 | $0.00 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · derivative · entry 22 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,742 shares Expires 2025-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F16 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 75 | $330.23 | $24,766.88 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 16 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,076 Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 967 | $329.86 | $318,974.72 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 15 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,151 F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $329.22 to $330.20, inclusive. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 400 | $328.68 | $131,472.48 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 14 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,118 F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.20 to $329.165, inclusive. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,000 | $327.63 | $327,626.80 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 13 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,518 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $327.19 to $328.18, inclusive. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 800 | $325.63 | $260,501.04 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 12 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,518 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.34 to $325.955, inclusive. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 900 | $324.69 | $292,218.03 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 11 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,318 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.16 to $324.84, inclusive. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,649 | $323.47 | $533,393.95 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 10 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 354,218 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.02 to $323.97, inclusive. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,951 | $322.45 | $629,099.56 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 9 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 355,867 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $322.02 to $323.00, inclusive. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 7,742 | $65.06 | $503,694.52 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 8 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $111.06 | $0.00 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · derivative · entry 21 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2025-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F16 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,728 | $0.00 Strike: $65.06 | $0.00 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · derivative · entry 20 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,742 Underlying: Common Stock · 1,728 shares Expires 2025-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F16 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $334.97 | $66,994.00 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 7 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,076 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.95 to $334.99, inclusive. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 800 | $333.66 | $266,926.00 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 6 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,276 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $333.39 to $333.89, inclusive. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,382 | $332.38 | $791,725.59 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 5 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,076 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $332.01 to $332.88, inclusive. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,759 | $331.36 | $914,220.58 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 4 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,458 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.00 to $331.89, inclusive. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,587 | $330.54 | $524,560.00 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 3 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,217 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.00 to $330.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 6,000 | $111.06 | $666,360.00 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 2 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 16:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 1,728 | $65.06 | $112,423.68 |
DisclosureSEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 1 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 16:46 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 520 | $315.90 | $164,269.98 |
DisclosureSEC source: 0001628280-24-050094 · wk-form4_1733435199.xml · nonDerivative · entry 2 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 11,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.84 to $316.16, inclusive. F2 · ownership.nature: Represents shares held indirectly by Dr. Craves through the Craves Family Foundation. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 16:46 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,080 | $315.21 | $970,851.73 |
DisclosureSEC source: 0001628280-24-050094 · wk-form4_1733435199.xml · nonDerivative · entry 1 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 11,520 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.00 to $315.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. F2 · ownership.nature: Represents shares held indirectly by Dr. Craves through the Craves Family Foundation. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 16:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,200 | $350.71 | $420,857.52 |
DisclosureSEC source: 0001628280-24-049400 · wk-form4_1732742168.xml · nonDerivative · entry 2 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 14,600 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.46 to $351.06, inclusive. F2 · ownership.nature: Represents shares held indirectly by Dr. Craves through the Craves Family Foundation. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 16:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,200 | $350.08 | $770,170.50 |
DisclosureSEC source: 0001628280-24-049400 · wk-form4_1732742168.xml · nonDerivative · entry 1 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 15,800 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. F2 · ownership.nature: Represents shares held indirectly by Dr. Craves through the Craves Family Foundation. Read SEC document |
| September 13, 2024 Filed Sep 17, 2024 20:36 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GiftCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-107561 · ownership.xml · nonDerivative · entry 1 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,076 Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 21:46 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 1,105 | $0.00 Strike: $280.04 | $0.00 |
DisclosureSEC source: 0000950170-24-078756 · ownership.xml · derivative · entry 5 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,105 Underlying: Common Stock · 1,105 shares Expires 2031-06-25 F5 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 21:46 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 714 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-078756 · ownership.xml · nonDerivative · entry 1 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,076 F1 · shares: Represents a grant of restricted stock units, which vest on June 25, 2025, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GiftCommon Stock | 45,852 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-073290 · ownership.xml · nonDerivative · entry 2 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 11,210 F1 · ownership.nature: Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GiftCommon Stock | 39,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-073290 · ownership.xml · nonDerivative · entry 1 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,362 Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (right to buy) · Derivative | 12,489 | $0.00 Strike: $105.08 | $0.00 |
DisclosureSEC source: 0000950170-24-061321 · ownership.xml · derivative · entry 17 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,489 shares Expires 2024-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The shares underlying this stock option are fully vested. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $100.45 | $0.00 |
DisclosureSEC source: 0000950170-24-061321 · ownership.xml · derivative · entry 16 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The shares underlying this stock option are fully vested. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 100 | $219.90 | $21,990.00 |
DisclosureSEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 12 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 413,362 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,000 | $218.99 | $218,994.50 |
DisclosureSEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 11 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 413,462 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.68 to $219.34 inclusive. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,100 | $217.86 | $239,640.83 |
DisclosureSEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 10 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 414,462 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.64 to $218.37 inclusive. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 721 | $216.98 | $156,445.32 |
DisclosureSEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 9 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 415,562 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.61 to $217.23 inclusive. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 375 | $216.08 | $81,031.35 |
DisclosureSEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 8 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 416,283 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.61 to $216.58 inclusive. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,804 | $214.68 | $387,285.43 |
DisclosureSEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 7 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 416,658 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.39 to $215.27 inclusive. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,190 | $213.85 | $468,342.01 |
DisclosureSEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 6 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 418,462 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.36 to $214.34 inclusive. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,363 | $212.85 | $290,116.32 |
DisclosureSEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 5 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 420,652 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.36 to $213.31 inclusive. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,009 | $211.84 | $1,061,126.60 |
DisclosureSEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 4 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 422,015 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.34 to $212.33, inclusive. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 8,827 | $210.99 | $1,862,431.68 |
DisclosureSEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 3 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 427,024 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.34 to $211.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 12,489 | $105.08 | $1,312,344.12 |
DisclosureSEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 2 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 435,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 10,000 | $100.45 | $1,004,500.00 |
DisclosureSEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 1 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 423,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 19:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | OtherCommon Stock | 46,073 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020582 · doc4.xml · nonDerivative · entry 2 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,261 F6 · kind: Represents transfers, without the payment of any consideration, to their partners and employees. F7 · shares: Includes 46,073 shares of Common Stock previously reported as indirectly held by Fund IV. F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), and Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and has sole voting and dispositive power with respect to the securities held by Fund IV. BCC, the manager of Management IV, is also an advisor to Fund IV and has sole voting and dispositive power with respect to the securities held by Fund IV. F3 · ownership.nature: These securities are held by BCC. Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 19:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | OtherCommon Stock | 1,510,521 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020582 · doc4.xml · nonDerivative · entry 1 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 F6 · kind: Represents transfers, without the payment of any consideration, to their partners and employees. F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), and Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and has sole voting and dispositive power with respect to the securities held by Fund IV. BCC, the manager of Management IV, is also an advisor to Fund IV and has sole voting and dispositive power with respect to the securities held by Fund IV. F2 · ownership.nature: These securities were held by Fund IV. Dr. Craves disclaims beneficial ownership of these securities previously held by Fund IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 18:46 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 1,198 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-016059 · doc4.xml · nonDerivative · entry 1 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,556 F1 · kind: Represents a grant of restricted stock units, which vest on June 15, 2024, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| January 30, 2023 Filed Dec 11, 2023 19:25 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GiftCommon Stock | 3,557 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020582 · doc4.xml · nonDerivative · entry 3 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 57,062 F4 · ownership.nature: Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust and reflects the transfer of 29,381 shares of Common Stock to the reporting person from the grantor retained annuity trust. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 06:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 9,470 | $0.00 Strike: $65.06 | $0.00 |
DisclosureSEC source: 0000899243-22-023232 · doc4.xml · derivative · entry 1 CRAVES FRED B · CIK 0001014095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,470 Underlying: Common Stock · 9,470 shares Expires 2025-06-16 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| December 31, 2021 Filed Feb 2, 2022 16:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-004133 · doc5.xml · nonDerivative · entry 1 CRAVES FRED B · CIK 0001014095 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,358 F1 · kind: Represents a bona fide gift of 3,000 shares of common stock from Dr. Craves to the Fred Craves Family Foundation. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 16:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | OtherCommon Stock | 24,172 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-047115 · doc4.xml · nonDerivative · entry 3 CRAVES FRED B · CIK 0001014095 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,261 F7 · kind: Represents transfers, without the payment of any consideration, to their partners and employees. F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. F4 · ownership.nature: These securities are held by BCC. Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 16:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | OtherCommon Stock | 49,730 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-047115 · doc4.xml · nonDerivative · entry 2 CRAVES FRED B · CIK 0001014095 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F7 · kind: Represents transfers, without the payment of any consideration, to their partners and employees. F7 · acquired: Represents transfers, without the payment of any consideration, to their partners and employees. F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. F3 · ownership.nature: These securities were held by Co-Investment IV. Dr. Craves disclaims beneficial ownership of these securities previously held by Co-Investment IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.